info@talent4boards.com

Faron Pharmaceuticals announces Greg Brown and John Poulos to its Board as upcoming Non-Executive Directors

– FINLAND, Turku – Faron Pharmaceuticals Ltd (AIM:FARN), the clinical stage biopharmaceutical company, is pleased to announce the proposed appointment of two new Non-Executive Directors, Dr. Gregory B. Brown and Mr John Poulos, to the Company’s Board. Pursuant to the requirements of Finnish law, the appointment of Dr. Brown and Mr Poulos remains subject to the approval of Shareholders at the Company’s Annual General Meeting which is to be held on 16 May 2017. The notice of the AGM will be published separately today.

Dr. Gregory B. Brown has more than 35 years of experience in healthcare and investment. Most recently, Greg founded HealthCare Royalty Partners, a healthcare-focused private asset management firm investing in biopharmaceutical and medical products, where he currently serves as Vice Chairman. In addition, Greg is currently a director of Caladrius Biosciences Inc (NASDAQ) and Nuron Biotech Inc and previously acted as a director of Invuity Inc (NASDAQ) between October 2014 and December 2015. Prior to this, he was a General Partner at Paul Capital Partners in New York, Co-Head of Investment Banking at Adams, Harkness & Hill, and VP of Corporate Finance at Vector Securities International.

Mr John Poulos has a wealth of expertise in global corporate life sciences, having spent 38 years working for AbbVie and Abbott. Most recently, John served as Vice President, Head of Licensing and Acquisitions for AbbVie, and Group Vice President, Head of Pharmaceutical Licensing and Acquisitions for Abbott Pharmaceuticals. During his career, John was instrumental in the negotiation of numerous acquisitions, including Knoll/BASF Pharma in 2001 for $6.9 billion and Solvay in 2010 for $6.2 billion.

In addition, Faron announces today that Dr Juho Jalkanen will, as of 16 May 2017, step down from the Board as Non-Executive Director, a position he has held since 2013. Dr Juho Jalkanen has this month been appointed to a new position of Vice President of Business Development of Faron and has joined the Management Team of the Company.

Commenting on the proposed Board changes, Dr Frank Armstrong, Chairman of Faron, said: “On behalf of the Board, it is with great pleasure that we propose the appointment of Greg and John to Faron. They will both bring a wealth of global experience in the life sciences and investment community to strengthen our Board, particularly from a US and commercial angle, as we continue to progress through a pivotal year. I also congratulate Juho on his new position as Vice President of Business Development and extend my gratitude to him for his contribution to the Board over the past four years. I am confident that these proposed additions to the Board will bring invaluable insights and perspectives to the Company.”

Dr. Brown was a director of Oscient Pharmaceuticals Inc (“Oscient”) between 2006 and 2009 having been initially elected to the board of Oscient as a representative of Paul Capital Partners, a financier which, during 2006, arranged financing of approximately $70 million in aggregate for Oscient. In July 2009, as a result of being unable to refinance an existing convertible debt, the directors of Oscient (being 9 board members in total) filed a voluntary petition for Chapter 11 Bankruptcy protection. Its assets were subsequently divested to satisfy the majority of creditors and Oscient was dissolved in July 2012.

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland.

For more information : http://www.faronpharmaceuticals.com

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here, the original post =>

Comments are closed.